Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia

Biochemical and Biophysical Research Communications

Volumn 413, Issue 2, 2011, Pages 212-217

  Pfeilschifter, Waltraud ^a   Czech Zechmeister, Bozena ^a   Sujak, Marian ^a   Mirceska, Ana ^a   Koch, Alexander ^a   Rami, Abdelhaq ^a   Steinmetz, Helmuth ^a   Foerch, Christian ^a   Huwiler, Andrea ^b   Pfeilschifter, Josef ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Experimental stroke; Lipids; Signal transduction

Indexed keywords

FINGOLIMOD; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN FUNCTION; BRAIN ISCHEMIA; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BRAIN ISCHEMIA; ENZYME ACTIVATION; GENE DELETION; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; SPHINGOSINE;

MUS; RODENTIA;

EID: 80053112315     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.070     Document Type: Article

References (24)

1. Rami A., Bechmann I., Stehle J.H. Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog. Neurobiol. 2008, 85:273-296.
2. Huwiler A., Pfeilschifter J. New players on center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem. Pharmacol. 2008, 75:1893-1900.
3. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009, 158:1173-1182.
4. Salomone S., Potts E.M., Tyndall S., et al. Analysis of sphingosine 1-phosphate receptors in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br. J. Pharmacol. 2008, 153:140-147.
5. Peng X., Hassoun P.M., Sammani S. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 2004, 169:1245-1251.
6. Bryan L., Kordula T., Spiegel S. Regulation and functions of sphingosine kinases in the brain. Biochim. Biophys. Acta 2008, 1781:459-466.
7. Spiegel S., Milstien S. Functions of the multifaceted family of sphingosine kinases, some close relatives. J. Biol. Chem. 2007, 282:2125-2129.
8. Igarashi N., Okada T., Hayashi S., et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 2003, 278:46832-46839.
9. Blondeau N., Lai Y., Tyndall S., et al. Distribution of sphingosine kinase activity and mRNA in rodent brain. J. Neurochem. 2007, 103:509-517.
10. Wacker B.K., Park T.S., Gidday J.M. Hypoxic preconditioning-induced cerebral ischemic tolerance. role of microvascular sphingosine kinase 2. Stroke 2009, 40:3342-3348.
11. Czech B., Pfeilschifter W., Mazaheri-Omrani N., et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem. Biophys. Res. Commun. 2009, 389:251-256.
12. Hasegawa Y., Suzuki Y.H., Sozen T., et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010, 41:368-374.
13. Wei Y., Yemisci M., Kim H.H., et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann. Neurol. 2011, 69:119-129.
14. Billich A., Bornancin F., Dévay P., et al. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 2003, 278:47408-47415.
15. Pushparaj P.N., Manikandan J., Tay H.K. Sphingosine kinase 1 is pivotal for Fc epsilon RI-mediated mast cell signaling and functional responses in vitro and in vivo. J. Immunol. 2009, 183:221-227.
16. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 2006, 26:1465-1478.
17. Ren S., Babelova A., Moreth K., et al. Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int. 2009, 76:857-867.
18. Zemann B., Kinzel B., Müller M. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006, 107:1454-1458.
19. Alemany R., Van Koppen C.J., Danneberg K. Regulation and functional roles of sphingosine kinases, Naunyn Schmiedebergs. Arch. Pharmacol. 2007, 374:413-428.
20. Hofmann L.P., Ren S., Schwalm S. Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol. Chem. 2008, 389:1399-1407.
21. Liu H., Toman R.E., Goparaju S.K., et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem. 2003, 278:40330-40336.
22. Jo S.K., Bajwa A., Ye H., et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int. 2009, 75:167-175.
23. Zemann B., Urtz N., Reuschel R., et al. Normal neutrophil functions in sphingosine kinase type 1 and 2 knockout mice. Immunol. Lett. 2007, 109:56-63.
24. Dudek S.M., Camp S.M., Chiang E.T., et al. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell. Signal. 2007, 19:1754-1764.